Clinical Trial Update: A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the safety and efficacy of osimertinib in combination with amivantamab for non-small cell lung cancer with common EGFR mutations. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)
• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING